Safety and Effectiveness of a Fixed-Dose Combination of Cephalexin Extended Release and Clavulanate Potassium in Bacterial Sore Throat and Uncomplicated Skin and Soft-Tissue Infections: A Multicentre, Open-Label, Phase IV Study in India | Synapse
January 25, 2026Open Access
Safety and Effectiveness of a Fixed-Dose Combination of Cephalexin Extended Release and Clavulanate Potassium in Bacterial Sore Throat and Uncomplicated Skin and Soft-Tissue Infections: A Multicentre, Open-Label, Phase IV Study in India
Puntos clave
To evaluate the safety and effectiveness of a fixed-dose combination of cephalexin and clavulanate potassium in bacterial infections.
Multicentre, open-label phase IV study design
Registered on Clinical Trials Registry, India
Focused on bacterial sore throat and uncomplicated skin and soft-tissue infections
Participants received fixed-dose combination treatment
Demonstrated positive safety profile for the combination treatment
Noted effectiveness in managing bacterial sore throat
Showed good outcomes for skin and soft-tissue infections
Resumen
This study was prospectively registered on Clinical Trials Registry, India CTRI/2022/07/044190 on 20 July, 2022; URL: https://ctri.nic.in/Clinicaltrials/pmaindet2.php?EncHid=NzA4MTA=&Enc=&userName= .